In the second episode of the series focusing on the use of AI in drug discovery, Nick is joined by Quentin Perron; CSO of Iktos. Iktos are a French biotech for ligand-based and structure-based de novo drug design focusing on multi-parametric optimization.

Quentin Perron is a medicinal chemist by training. He holds a PhD in organometallic chemistry from the University of Geneva. During his post-doc fellowship at UCLA, he worked on the total synthesis of Brasillicardin A, a complex natural molecule known for having potent immunosuppressive activity. After working as a medicinal chemist in CNS indications at Laboratoires Servier, he switched to data science and chemoinformatics at Quinten, a company specialising in data science services. In 2016, with his business partners Yann Gaston-Mathé and Nicolas Do Huu, he co-founded Iktos, a start-up company developing AI technologies for new drug design. He is now the CSO of the company.

To speak to Nick, please drop an email to [email protected]